HIF1α
HIF1α (hypoxia-inducible factor 1 alpha) is a gene encoding the Oxygen-sensitive subunit of the HIF-1 transcription factor complex, a central regulator of cellular adaptation to hypoxia.
HIF1α (hypoxia-inducible factor 1 alpha) is a gene encoding the Oxygen-sensitive subunit of the HIF-1 transcription factor complex, a central regulator of cellular adaptation to hypoxia. Under low-Oxygen conditions, HIF1α accumulates and drives transcriptional programs that promote glycolysis, angiogenesis, survival, and metabolic reprogramming. Because of this role, HIF1α is widely studied in Cancer, inflammation, ischemic injury, neurodegeneration, and metabolic disease.
In biomedical research, HIF1α is often treated as a Signaling hub rather than a standalone endpoint, since it integrates upstream stress signals such as Mitochondrial Reactive Oxygen Species, inflammatory pathways, and metabolic perturbations. Recent studies have examined HIF1α in relation to the HIF1α/NF-κB axis, HIF1α/PFKFB3 Signaling, and broader hypoxia-linked metabolic pathways, including the Warburg effect and glycolytic reprogramming.
Rebuilt from PubMed 10 Sept 2026 · no new papers today
Where the papers sit
8 papers study hif1α directly. Those 8 do not group into themes. HIF1α appears here as a biomarker, therapeutic target, and mediator of hypoxia, inflammation, ferroptosis, and cancer. The diseases and mechanisms do not converge on a shared direction. They are no more alike than papers drawn from anywhere in the corpus. 2 new directions follow.
HIF-1α lactylation directly controls hypoxia-driven transcriptional complex assembly in esophageal cancer
Esophageal squamous cell carcinoma under hypoxia was found to use lactylation at HIF-1α K172 to promote binding to HIF-1β and assembly of the active HIF-1 transcription complex, rather than treating HIF-1α only as a hypoxia-responsive factor or therapeutic target. This identifies a specific post-translational control point linking lactylation to immune evasion and suggests that disrupting HIF-1α lactylation or complex formation could enhance antitumor immunity 42061805Apr.
HIF-1α can function as an effector of nanoplastic-induced ferroptotic ovarian injury
Maternal polystyrene-nanoplastic exposure in mice and ovarian granulosa-cell models showed that HIF-1α activation through the HIF-1α/HO-1 axis contributed to iron accumulation, lipid peroxidation, and ferroptosis, rather than merely supporting adaptation to stress. Pharmacological HIF-1α inhibition rescued cell viability, placing HIF-1α within a nanoplastic-induced reproductive-toxicity and ferroptosis mechanism not represented by the other papers 42285443Jun.
Recent Findings on HIF1α
Hypoxia-Linked Disease Biology: HIF1α connects hypoxia, inflammation, altered metabolism, and tissue injury across cancer, metabolic syndrome, ferroptosis, ischemia, gallstone disease, and neuroinflammation 42709845Sep42285443Jun42177905May42043510Apr42024486Apr. In antiretroviral therapy-treated people living with HIV, higher CRP and fibrinogen identified metabolic syndrome, while the HIF-1α rs11549465 CT + TT genotype associated with higher IL-6 42709845Sep. Polystyrene nanoplastics activated the HIF-1α/HO-1 axis and ferroptosis in offspring ovarian granulosa cells, whereas LW6 or Ferrostatin-1 rescued viability and hormone synthesis 42285443Jun. Cancer models support HIF1α inhibition as a therapeutic strategy: benzimidazole derivative 9o suppressed HIF-1α transcription and glycolysis, while PX-478 improved CD8+ T-cell activity and strengthened anti-PD-1 therapy 42418254Jul42061805Apr. PARP-inhibited ovarian cancer cells instead used mitochondrial reactive oxygen species to stabilize HIF1α and sustain glycolysis-dependent senescence-like survival 41980461Apr. Parthenolide reduced microglial inflammation, amyloidogenic processing, and pathology through the HIF1α/NF-κB axis, while other studies are evaluating HIF1α for acute mesenteric ischemia diagnosis and emodin-mediated gallstone prevention 42024486Apr42043510Apr42177905May.
Written from 8 PubMed abstracts, each one cited by PMID above. Published: 2026-06-24. Last written: 2026-09-10 by GPT. Drafted by language models from published abstracts; not medical advice.